Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Silo Pharma, Inc. Director's Dealing 2025

Dec 17, 2025

35304_dirs_2025-12-16_7c6f7412-4ab6-4ac8-a9cf-3db648eac67e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Silo Pharma, Inc. (SILO)
CIK: 0001514183
Period of Report: 2025-12-15

Reporting Person: Weisblum Eric (Director, Chief Executive Officer)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2025-12-15 Common Stock P 2500 $0.41 Acquired 214432 Direct
2025-12-15 Common Stock P 2500 $0.42 Acquired 216932 Direct